Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis

被引:29
|
作者
Peng, Hao [1 ]
Chen, Lei [1 ]
Li, Wen-Fei [1 ]
Zhang, Yuan [1 ]
Liu, Li-Zhi [2 ]
Tian, Li [2 ]
Lin, Ai-Hua [3 ]
Sun, Ying [1 ]
Ma, Jun [1 ]
机构
[1] Sun Yat Sen Univ, Dept Radiat Oncol, Ctr Canc, State Key Lab Oncol Southern China,Collaborat Inn, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Imaging Diag & Intervent Ctr, Ctr Canc, State Key Lab Oncol Southern China,Collaborat Inn, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou, Guangdong, Peoples R China
关键词
Nasopharyngeal carcinoma; Locoregionally advanced; Neoadjuvant chemotherapy; Intensity-modulated radiotherapy; Prognosis; PLUS ADJUVANT CHEMOTHERAPY; PHASE-II TRIAL; CONCURRENT CHEMORADIOTHERAPY; RANDOMIZED-TRIAL; INDUCTION CHEMOTHERAPY; PROGNOSTIC VALUE; CISPLATIN; CARBOPLATIN; SURVIVAL; CANCER;
D O I
10.1016/j.oraloncology.2016.10.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The aim of this study is to optimize the cycle for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) receiving neoadjuvant chemotherapy (NCT) in the era of intensity-modulated radiotherapy (IMRT). Materials and methods: Data on 569 locoregionally advanced NPC patients treated with IMRT were retrospectively reviewed. Propensity score matching (PSM) method was adopted to balance prognostic factors and match patients. Survival outcomes of matched patients between different NCT cycle groups were compared. Results: The median cycle of NCT was 2 (range, 2-4 cycles) for the whole cohort, and patients were therefore stratified as low cycle (= 2) and high cycle (> 2) groups. In total, 247 pairs of NPC patients were selected by PSM. Univariate analysis found no significantly prognostic difference between the low cycle and high cycle groups, and multivariate analysis did not establish NCT cycle as an independent factor. However, stratified analysis revealed patients in the low cycle group had better OS than those of patients in the high cycle group (92.4% vs. 80.8%, P = 0.029), and NCT was identified as an independent prognostic factor for OS in patients with N2-3 category (HR, 2.252; 95% CI, 1.024-4.953; P = 0.043). Conclusion: Two cycles of NCT may be enough and additional more cycles are not associated with improved survival outcomes for patients with locoregionally advanced NPC in the era of IMRT. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:78 / 84
页数:7
相关论文
共 50 条
  • [1] Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis
    Fangzheng Wang
    Chuner Jiang
    Lai Wang
    Fengqin Yan
    Quanquan Sun
    Zhimin Ye
    Tongxin Liu
    Zhenfu Fu
    Yangming Jiang
    [J]. Scientific Reports, 10
  • [2] Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy
    Wee, Chan Woo
    Keam, Bhumsuk
    Heo, Dae Seog
    Sung, Myung-Whun
    Won, Tae-Bin
    Wu, Hong-Gyun
    [J]. RADIATION ONCOLOGY JOURNAL, 2015, 33 (02): : 98 - 108
  • [3] y Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis
    Wang, Fangzheng
    Jiang, Chuner
    Wang, Lai
    Yan, Fengqin
    Sun, Quanquan
    Ye, Zhimin
    Liu, Tongxin
    Fu, Zhenfu
    Jiang, Yangming
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [4] Optimize the number of cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
    Jiang, YuTing
    Chen, KaiHua
    Yang, Jie
    Liang, ZhongGuo
    Qu, Song
    Li, Ling
    Zhu, XiaoDong
    [J]. JOURNAL OF CANCER, 2022, 13 (02): : 426 - 435
  • [5] Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis
    Chen, Jiawei
    Ding, Jianming
    Xu, Yiying
    Hong, Huiling
    Lin, Xiaoting
    Xu, Mengting
    Yan, Linghui
    Xu, Ting
    Fei, Zhaodong
    Chen, Chuanben
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (08)
  • [6] Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy
    Wen-Fei Li
    Ying-Qin Li
    Lei Chen
    Yuan Zhang
    Rui Guo
    Fan Zhang
    Hao Peng
    Ying Sun
    Jun Ma
    [J]. BMC Cancer, 15
  • [7] Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy
    Li, Wen-Fei
    Li, Ying-Qin
    Chen, Lei
    Zhang, Yuan
    Guo, Rui
    Zhang, Fan
    Peng, Hao
    Sun, Ying
    Ma, Jun
    [J]. BMC CANCER, 2015, 15
  • [8] Locoregionally advanced nasopharyngeal carcinoma in childhood and adolescence: Analysis of 95 patients treated with combined chemotherapy and intensity-modulated radiotherapy
    Guo, Qiaojuan
    Cui, Xiaofei
    Lin, Shaojun
    Lin, Jin
    Pan, Jianji
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E665 - E672
  • [9] Intensity-modulated radiotherapy combined with sequential cisplatin and fluorouracil chemotherapy for locoregionally advanced nasopharyngeal carcinoma
    Wu, Mingyao
    He, Xiayun
    Hu, Chaosu
    [J]. MEDICINE, 2018, 97 (50)
  • [10] Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
    Wang, Fangzheng
    Sun, Quanquan
    Jiang, Chuner
    Liu, Tongxin
    Rihito, Aizawa
    Masoto, Sakamoto
    Wang, Yuezhen
    Fu, Zhenfu
    Chen, Ming
    [J]. JOURNAL OF CANCER, 2018, 9 (03): : 594 - 603